• Brandon Stretton, Joshua Kovoor, Stephen Bacchi, Shantel Chang, Benjamin Ngoi, Tess Murray, Thomas C Bristow, Jonathan Heng, Aashray Gupta, Christopher Ovenden, Guy Maddern, Campbell H Thompson, Leonie Heilbronn, Mark Boyd, Christopher Rayner, Nicholas J Talley, and Michael Horowtiz.
• Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia.
• Intern Med J. 2023 Aug 1; 53 (8): 131113201311-1320.

AbstractGlucagon-like peptide 1 receptor agonists (GLP-1 RAs) reduce elevated blood glucose levels and induce weight loss. Multiple GLP-1 RAs and one combined GLP-1/glucose-dependent insulinotropic polypeptide agonist are currently available. This review was conducted with the aim of summarising direct comparisons between subcutaneous semaglutide and other GLP-1 RAs in individuals with type 2 diabetes (T2D), particularly with respect to efficacy for inducing weight loss and improving other markers of metabolic health. This systematic review of PubMed and Embase from inception to early 2022 was registered on PROSPERO and was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses and Meta-Analysis of Observational Studies in Epidemiology guidelines. Of the 740 records identified in the search, five studies fulfilled the inclusion criteria. Comparators included liraglutide, exenatide, dulaglutide and tirzepatide. In the identified studies, multiple dosing regimens were utilised for semaglutide. Randomised trials support the superior efficacy of semaglutide over other GLP-1 RAs with respect to weight loss in T2D, but tirzepatide is more effective than semaglutide.© 2023 The Authors. Internal Medicine Journal published by John Wiley & Sons Australia, Ltd on behalf of Royal Australasian College of Physicians.

12 keywords...

hide…